PDF-Safety Information and Unanticipated Problems Reporting
Author : trish-goza | Published Date : 2015-11-22
Objectives This presentation will address the following issues 149What events must be promptly reported to the Quorum Review institutional review board 149When and
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Safety Information and Unanticipated Pro..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Safety Information and Unanticipated Problems Reporting: Transcript
Objectives This presentation will address the following issues 149What events must be promptly reported to the Quorum Review institutional review board 149When and how such events must be repor. This guidance represents OHRP's current thinking on this topic and should be viewed as recommendations unless specific regulatory requirements are cited. The use of the word should in OHRP guidance Reporting: . Who, What, When, and Why. February, 2012. CASE #1- A Serious Adverse Event. The Background:. A PI became aware of a local unanticipated serious adverse event on January 1, 2012. It was not reported to the IRB by the PI until January 25, 2012, as part of a continuing review submission. . Melody Lin, Ph.D.. December,12. 2012. Unanticipated problems involving risk to participants or others. Is . unexpected . Is . related or possibly related . to participation in the research, and. Indicates that subjects or others are at a . , Unanticipated . Problems, and Protocol Deviations. Kathleen O’Malley RN, BSN, CCRP. Manager of Education and Training. Jefferson Clinical Research Institute. Kathleen.omalley@jefferson.edu. 1. Learning Objectives: Adverse Events. 15. th. FERCAP International Conference. 24 Nov 15. Nagasaki, Japan . Bussara Sukpanichnant, CIP. USAMD-AFRIMS. 1. Why I need to know about Unanticipated Problems?. Unanticipated Problem Involving Risks . 15. th. FERCAP International Conference. 24 Nov 15. Nagasaki, Japan . Bussara Sukpanichnant, CIP. USAMD-AFRIMS. 1. Why I need to know about Unanticipated Problems?. Unanticipated Problem Involving Risks . . Professor Burton. Fall 2016. November 1, 2016. Second Mid-Term Coming Up. Thursday, November 10. th. Will cover CAPM and APT (as well as . everything else . in class, . powerpoints. , readings). November 1, 2016. Provincial Quality Assurance workshops. Quality Assurance. COO’s Office. Ronel Steinh. öbel. Contents. Background. Purpose . Legal and policy framework. Scope . Definitions. Mandatory requirements. Office of Research Oversight Reporting: Who, What, When, and Why February, 2012 CASE #1- A Serious Adverse Event The Background: A PI became aware of a local unanticipated serious adverse event on January 1, 2012. It was not reported to the IRB by the PI until January 25, 2012, as part of a continuing review submission. Problems, and Protocol Deviations. Kathleen O’Malley RN, BSN, CCRP. Manager of Education and Training. Jefferson Clinical Research Institute. Kathleen.omalley@jefferson.edu. 1. Learning Objectives: Adverse Events. Human Research Protection Program (HRPP). HRPP COMPLIANCE AND QUALITY TEAM . Yale University. . Federal regulations (45 CFR 46 & 21 CFR 56) require institutions to establish written procedures for ensuring prompt reporting of any unanticipated problems involving risks to subjects or others (UPIRSOs) to the IRB, appropriate institutional officials, and the federal department or agency head.. UVM Research Protections Office. Unanticipated Problems (UAPs). The IRB is responsible per federal guidelines to review any unanticipated problems involving risks to subjects or others occurring in approved research (FDA: 21 CFR 56.108 (b)(1) & DHHS: 45 CFR 46.103(b)(5)(. Version 04 . Feb. 2021. In . this. . training course you will learn. What. is . pharmacovigilance. ?. What is the pharmacovigilance responsibility of the investigator in a clinical trial?. What is the pharmacovigilance responsibility of the sponsor in a clinical trial?. RIPARTITE PPROVAL AFETY ANAGEMENTEFINITIONS AND TANDARDS FOR XPEDITED E2D Step 4 dated 12 November 2003 This Guideline has been developed by the appropriate ICH Expert Working Group and has the r
Download Document
Here is the link to download the presentation.
"Safety Information and Unanticipated Problems Reporting"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents